Showing results (761-770 of 828) with videos related to
Sort By:
Pageof 83
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019Costanza Paoletti, Yufeng Li, Maria C Muñiz, et al.The Lancet. Oncology|January 9, 2023
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trialEve Rodler, Priyanka Sharma, William E Barlow, et al.Journal of Translational Medicine|July 4, 2012
Considerations in the development of circulating tumor cell technology for clinical useDavid R Parkinson, Nicholas Dracopoli, Brenda Gumbs Petty, et al.Journal of the National Cancer Institute|July 16, 2026
Recurrence Score® gene group components and outcomes in the RxPONDER trial (SWOG S1007)Yara Abdou, Jess Hoag, William E Barlow, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2020
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline UpdateKimberly H Allison, M Elizabeth H Hammond, Mitchell Dowsett, et al.The Pharmacogenomics Journal|September 4, 2013
Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancerS Yao, L E Sucheston, H Zhao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2025
Novel Postneoadjuvant Prognostic Breast Cancer Staging SystemDavid J Winchester, Lavisha Singh, Stephen B Edge, et al.Breast Cancer Research and Treatment|July 19, 2011
Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221)Lara E Sucheston, Hua Zhao, Song Yao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2020
Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORxLynne I Wagner, Robert J Gray, Joseph A Sparano, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateAntonio C Wolff, M Elizabeth H Hammond, David G Hicks, et al.Pageof 83